文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

评估NI-03在慢性胰腺炎患者中药代动力学、安全性和有效性的1/2期试验:卡莫司他治疗慢性胰腺炎随机对照试验(TACTIC)研究方案

A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC).
PubMed 文献 · Trials · 2019-08-14

慢性胰腺炎相关疼痛目前尚无获批药物治疗,NI-03(甲磺酸卡莫司他)是一种口服丝氨酸蛋白酶抑制剂,在日本已广泛用于治疗慢性胰腺炎相关疼痛。本研究在美国开展1/2期试验:1期单次给药(100、200或300 mg)评估药代动力学和安全性,2期采用双盲随机对照试验评估三种剂量每日三次给药28天相比安慰剂的疗效,主要终点为研究期最后7天每日最严重疼痛评分均值较基线的变化。

要点

  • 慢性胰腺炎相关疼痛目前无获批药物治疗,NI-03在日本已广泛用于该适应症。
  • 1期评估单次给药100、200或300 mg的药代动力学和安全性。
  • 2期双盲随机对照试验评估三种剂量每日三次给药28天相比安慰剂的疗效。

核心结论

  • NI-03在日本已成功且安全地用于治疗慢性胰腺炎相关疼痛,本研究旨在通过严格的随机对照试验评估其在美国人群中的安全性和有效性。
  • 本研究可能填补为慢性胰腺炎相关疼痛提供有效药物治疗选择的重要临床空白。

研究设计与样本

  • 研究分为两阶段:先进行1期研究,单次给药(100、200或300 mg)后1周内确定药代动力学和安全性特征。
  • 随后进行2期双盲随机对照试验,评估三种剂量NI-03每日三次给药相比安慰剂28天的疗效。
  • 双盲阶段前设7天单盲导入期以评估基线疼痛特征。

主要发现

  • 主要疗效终点为研究期最后7天每日最严重疼痛评分(0-10数字评定量表)均值较基线的变化。
  • 次要疗效终点包括阿片类药物剂量变化、生活质量指标及首次补救性静脉镇痛药使用时间。
  • 记录不良事件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic pancreatitis (CP) is a progressive, fibro-inflammatory disease characterized by enzymatic autoactivation and subsequent fibrotic replacement of acinar cells. A significant proportion of patients develop pain, which may be due to many causes, including perineural inflammation, altered central processing of pain signals, parenchymal structural changes, and ductal obstruction. Currently there are no approved medical treatment options for CP-associated pain. NI-03 (camostat mesilate) is an orally administered serine protease inhibitor that reduces pancreatic enzyme activity and has been widely used for the treatment of CP-associated pain in Japan. The current study will assess the safety and efficacy of NI-03 for reduction of CP-associated pain in the USA. METHODS: The current study consists of two phases. First, a phase I study will be performed to establish the pharmacokinetics and safety profile over a 1-week period following a single dose (100, 200, or 300 mg). Subsequently, a phase II study will be performed consisting of a double-blind, randomized, controlled trial (RCT). This RCT will evaluate the efficacy of each of the three doses of NI-03 given three times daily compared to placebo over 28 days. A 7-day, single-blind, run-in period will precede the double-blind phase to assess baseline pain characteristics. The primary efficacy outcome is the average of worst daily pain scores (numeric rating scale of 0-10) over the terminal 7 days of the study period compared to baseline. Secondary efficacy outcomes include change in opioid dose and quality of life measures, and time to first rescue intravenous analgesic. Adverse events will be recorded. DISCUSSION: NI-03 has been used successfully and safely in Japan to treat CP-associated pain. The aim of the current study is to assess the safety and efficacy of NI-03 using a rigorous RCT in a population in the USA. This study may fill an important clinical gap to provide an effective medical treatment option for CP-associated pain. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02693093 . Registered through the National Institutes of Health on 26 February 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ramsey ML, Nuttall J, Hart PA, et al. A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). Trials. 2019. PMID: 31412955. doi:10.1186/s13063-019-3606-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。